Asymptomatic SARS-CoV-2 infection in two patients with multiple sclerosis treated with fingolimod

Mult Scler Relat Disord. 2020 Oct:45:102414. doi: 10.1016/j.msard.2020.102414. Epub 2020 Jul 19.

Authors

Giulia Mallucci¹, Antonio Zito², Beatrice Dal Fabbro², Roberto Bergamaschi²

Affiliations

¹ Multiple Sclerosis Centre, IRCCS Mondino Foundation, via Mondino 2, 27100, Pavia, Italy; Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy. Electronic address: giulia.mallucci@mondino.it.
² Multiple Sclerosis Centre, IRCCS Mondino Foundation, via Mondino 2, 27100, Pavia, Italy.

No abstract available

Keywords: COVID-19; Fingolimod; Multiple sclerosis; SARS-CoV-2.

Publication types

Case Reports
Letter

MeSH terms

Adult
Asymptomatic Diseases / therapy*
Betacoronavirus*
COVID-19
Coronavirus Infections / complications
Coronavirus Infections / diagnosis
Coronavirus Infections / drug therapy*
Fingolimod Hydrochloride / therapeutic use*
Humans
Immunosuppressive Agents / therapeutic use*
Middle Aged
Multiple Sclerosis / complications
Multiple Sclerosis / diagnosis
Multiple Sclerosis / drug therapy*
Pandemics
Pneumonia, Viral / complications
Pneumonia, Viral / diagnosis
Pneumonia, Viral / drug therapy*
SARS-CoV-2
Treatment Outcome

Substances

Immunosuppressive Agents
Fingolimod Hydrochloride